Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2021 Publisher: Aventis Pharma Limited, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK Trading as: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
Adenoscan 30 mg/10 ml solution for infusion.
| Pharmaceutical Form |
|---|
|
Solution for infusion. Adenoscan is a sterile clear, colourless solution. |
Each 10 ml vial of Adenoscan contains 30 mg of adenosine (3 mg/ml).
Excipient with known effect:
Each vial contains 1.54 mmol of sodium, which is 35.4 mg sodium.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Adenine Deoxy Nucleoside |
Adenosine is a purine nucleoside which is present in all cells of the body. Animal pharmacology studies have in several species shown that adenosine has a negative dromotropic effect on the atrioventricular (AV) node. |
| List of Excipients |
|---|
|
Sodium chloride |
Type I glass vials with chlorobutyl rubber stoppers, packs with 6 vials.
Aventis Pharma Limited, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
Trading as:
Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
PL 04425/0682
Date of first authorisation: 03 May 1995
Date of latest renewal: 03 May 2010
| Drug | Countries | |
|---|---|---|
| ADENOSCAN | Spain, France, Hong Kong, Japan, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
